Medial EarlySign Appoints Chief Medical Officer

KFAR MALAL, Israel, July 10, 2018 /PRNewswire/ --

Medial EarlySign (http://www.earlysign.com), a leader in machine learning-based solutions to improve disease management, today announced that Jeremy Orr, MD, MPH, has been appointed Chief Medical Officer (CMO).

The appointment emphasizes Medial EarlySign's commitment to providing precise insights to healthcare organizations, utilizing AI and machine learning algorithms that leverage existing Electronic Health Record (EHR) data. These insights help determine the best approach to improving patients' health and enhance organizations' abilities to provide proactive care.

"Predictive analytics provide physicians and healthcare organizations with a powerful tool for early identification and intervention for high-risk patients," said Dr. Orr. "I am proud to be playing a significant role with EarlySign. The company's technology has been proven to enable more effective care management with the potential to positively impact millions of lives."

Dr. Orr brings more than 20 years of experience as a practicing physician, executive and healthcare IT entrepreneur. He previouslyserved as CMO of clinical decision support company Stanson Health. He also served as CMO of Humedica, a healthcare analytics company acquired by Optum, which provides clinical business intelligence solutions. Prior to his career as a health IT executive, Dr. Orr was a practicing physician at Kaiser Permanente where he was named a "Top 100 Physician." He then went on to launch his own medical practice that later became part of Centura Health. Dr. Orr received his MD from the State University of New York at Buffalo and his MPH in Epidemiology from Tulane University.

"Medial EarlySign has emerged as a medical algorithm trailblazer, and we are excited to welcome Dr. Orr as our new Chief Medical Officer," said Ori Geva, CEO and Co-founder of Medial EarlySign. "Dr. Orr brings extensive experience in patient care and healthcare IT and we believe he will contribute significantly in further broadening our suite of solutions and expanding global implementations of our clinically-validated technology."

About Medial EarlySign 
Medial EarlySign's advanced AI-based algorithm platform helps healthcare organizations accurately stratify populations to optimize care for individuals and prevent or delay serious health conditions, by leveraging routine blood test results, and common labs and EHR data. The company creates actionable opportunities for better clinical decision making and early intervention to improve patient outcomes, focus financial resources, and reduce overall costs. Medial EarlySign is developing a suite of AlgoMarker™ stratification models to address a variety of illnesses including cancers, diabetes and associated complications and other life-threatening conditions. The company's platform has been supported by peer-reviewed research published by internationally recognized health organizations and hospitals. Founded in 2009, Medial EarlySign is headquartered in Kfar Malal, Israel. For more information, please visit http://earlysign.com/.

Follow Medial EarlySign on LinkedIn: Medial EarlySign and Twitter: @MedialEarlySign

Media Relations Contact: 
Ellie Hanson
Finn Partners
+1-929-222-8006
[email protected]

SOURCE Medial EarlySign

[ Back To TMCnet.com's Homepage ]